Romain Remark
Overview
Explore the profile of Romain Remark including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
5761
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Demaria O, Habif G, Vetizou M, Gauthier L, Remark R, Chiossone L, et al.
Sci Immunol
. 2024 Nov;
9(101):eadp3720.
PMID: 39546590
NK cells offer a promising alternative to T cell therapies in cancer. We evaluated IPH6501, a clinical-stage, tetraspecific NK cell engager (NKCE) armed with a non-alpha IL-2 variant (IL-2v), which...
2.
Blery M, Mrabet-Kraiem M, Morel A, Lhospice F, Bregeon D, Bonnafous C, et al.
Open Res Eur
. 2023 Aug;
1:107.
PMID: 35967081
MICA and MICB are tightly regulated stress-induced proteins that trigger the immune system by binding to the activating receptor NKG2D on cytotoxic lymphocytes. MICA and MICB are highly polymorphic molecules...
3.
Playoust E, Remark R, Vivier E, Milpied P
Cell Mol Immunol
. 2023 Jul;
20(9):1040-1050.
PMID: 37419983
B cells play essential roles in immunity, mainly through the production of high affinity plasma cells (PCs) and memory B (Bmem) cells. The affinity maturation and differentiation of B cells...
4.
Demaria O, Gauthier L, Vetizou M, Alvarez A, Vagne C, Habif G, et al.
Cell Rep Med
. 2022 Oct;
3(10):100783.
PMID: 36260981
Harnessing innate immunity is emerging as a promising therapeutic approach in cancer. We report here the design of tetraspecific molecules engaging natural killer (NK) cell-activating receptors NKp46 and CD16a, the...
5.
Bonnereau J, Courau T, Asesio N, Salfati D, Bouhidel F, Corte H, et al.
Gut
. 2022 Jul;
72(4):699-709.
PMID: 35803702
Objective: T cells are major effectors of the antitumoural immune response. Their activation by tumour-associated antigens can unleash their proliferation and cytotoxic functions, leading to tumour cell elimination. However, tumour-related...
6.
Mortha A, Remark R, Del Valle D, Chuang L, Chai Z, Alves I, et al.
Gastroenterology
. 2022 May;
163(3):659-670.
PMID: 35623454
Background & Aims: Anti-granulocyte macrophage-colony stimulating factor autoantibodies (aGMAbs) are detected in patients with ileal Crohn's disease (CD). Their induction and mode of action during or before disease are not...
7.
Carvelli J, Demaria O, Vely F, Batista L, Chouaki Benmansour N, Fares J, et al.
Nature
. 2020 Jul;
588(7836):146-150.
PMID: 32726800
Coronavirus disease 2019 (COVID-19) is a disease caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has resulted in a pandemic. The C5a complement factor and its...
8.
Fernandez D, Rahman A, Fernandez N, Chudnovskiy A, Amir E, Amadori L, et al.
Nat Med
. 2019 Oct;
25(10):1576-1588.
PMID: 31591603
Atherosclerosis is driven by multifaceted contributions of the immune system within the circulation and at vascular focal sites. However, specific characteristics of dysregulated immune cells within atherosclerotic lesions that lead...
9.
Akturk G, Sweeney R, Remark R, Merad M, Gnjatic S
Methods Mol Biol
. 2019 Sep;
2055:497-519.
PMID: 31502167
Disease states and cellular compartments can display a remarkable amount of heterogeneity, and truly appreciating this heterogeneity requires the ability to detect and probe each subpopulation present. A myriad of...
10.
Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, et al.
Cell
. 2019 Jun;
177(7):1701-1713.e16.
PMID: 31155232
Over the last decade, various new therapies have been developed to promote anti-tumor immunity. Despite interesting clinical results in hematological malignancies, the development of bispecific killer-cell-engager antibody formats directed against...